Last reviewed · How we verify
Amlodipine/Atorvastatin
This combination drug reduces blood pressure by blocking calcium channels in blood vessels and lowers cholesterol by inhibiting HMG-CoA reductase.
This combination drug reduces blood pressure by blocking calcium channels in blood vessels and lowers cholesterol by inhibiting HMG-CoA reductase. Used for Hypertension and dyslipidemia in patients requiring both agents, Reduction of cardiovascular risk in patients with coronary artery disease or multiple cardiovascular risk factors.
At a glance
| Generic name | Amlodipine/Atorvastatin |
|---|---|
| Also known as | Caduet |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Calcium channel blocker / HMG-CoA reductase inhibitor (statin) combination |
| Target | L-type voltage-gated calcium channels / HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amlodipine is a dihydropyridine calcium channel blocker that relaxes vascular smooth muscle and reduces peripheral vascular resistance, thereby lowering blood pressure. Atorvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and triglycerides while raising HDL cholesterol. Together, they address two major cardiovascular risk factors.
Approved indications
- Hypertension and dyslipidemia in patients requiring both agents
- Reduction of cardiovascular risk in patients with coronary artery disease or multiple cardiovascular risk factors
Common side effects
- Headache
- Edema (peripheral)
- Flushing
- Muscle pain (myalgia)
- Elevated liver enzymes
- Dizziness
Key clinical trials
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (PHASE4)
- A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE) (PHASE4)
- Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage (NA)
- Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)
- The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications. (NA)
- Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults
- Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: